Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit

Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2014, Pages 324-330

  Cheatham, S Christian ^a   Fleming, Megan R ^b   Healy, Daniel P ^c   Chung, Eun Kyoung ^d   Shea, Katherine M ^e   Humphrey, Melissa L ^d   Kays, Michael B ^d  

^a Department of Pharmacy Franciscan St Francis Health ^*  (United States)

^b METHODIST DALLAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^d PURDUE UNIVERSITY   (United States)

^e University Medical Center Brackenridge   (United States)

Author keywords

meropenem; obesity; pharmacodynamics; pharmacokinetics

Indexed keywords

MEROPENEM;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORBID OBESITY; STANDARD; STEADY STATE;

MEROPENEM; OBESITY; PHARMACODYNAMICS; PHARMACOKINETICS;

AGED; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; OBESITY, MORBID; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 84898664892     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.196     Document Type: Article

References (31)

1. World Health Organization. Obesity and overweight. Geneva, Switzerland: WHO; 2012. Fact sheet No. 311. http://www.who.int/mediacentre/factsheets/fs311/ en [accessed 11.07.13].
2. Food and Agriculture Organization. The state of food and agriculture: foods systems for better nutrition. Rome, Italy: FAO: 2013. http://www.fao.org/ docrep/018/i3300e/i3300e.pdf [accessed 11.07.13].
3. Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012; 10: 22.
4. Flegal KM, Carroll MD, Kit BK, Ogden CL., Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307: 483-490.
5. Public Health England. Adult weight fact sheet. http://www.noo.org.uk/ uploads/doc/vid-16201-AdultWeightFactsheetJuly2012-v2.pdf [accessed 11.07.13].
6. Dellit TH, Owens RC, McGowan JE, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177. (Pubitemid 46084814)
7. Pai MP, Bearden DT., Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2007; 27: 1081-1091. (Pubitemid 47173654)
8. Janson B, Thursky K., Dosing of antibiotics in obesity. Curr Opin Infect Dis. 2012; 25: 634-649.
9. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011; 90: 77-89.
10. Lodise TP, Lomaestro BM, Drusano GL., Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy. 2006; 26: 1320-1332.
11. Li C, Du X, Kuti JL, Nicolau DP., Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007; 51: 1725-1730. (Pubitemid 46744151)
12. Cheatham SC, Kays MB, Smith DW, Wack MF, Sowinski KM., Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients. Pharmacotherapy. 2008; 28: 691-698. (Pubitemid 351975372)
13. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med. 2005; 171: 388-416.
14. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother. 1994; 38: 151-154. (Pubitemid 24018175)
15. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother. 1999; 43: 523-527. (Pubitemid 29182302)
16. de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P., Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother. 2000; 46: 150-151. (Pubitemid 30466217)
17. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA., Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents. 2002; 19: 105-110. (Pubitemid 34168176)
18. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GKM, Zelenitsky SA., Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005; 39: 32-38. (Pubitemid 40052375)
19. Jaruratanasirikul S, Sriwiriyajan S, Punyo J., Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother. 2005; 49: 1337-1339. (Pubitemid 40463358)
20. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR., Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005; 44: 539-549. (Pubitemid 40733738)
21. Kim A, Kuti JL, Nicolau DP., Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther. 2009; 31: 2765-2778.
22. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP., Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther. 2010; 32: 766-779.
23. Demirovic JA, Pai AB, Pai MP., Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009; 66: 642-648.
24. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F., High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B. 1996; 686: 19-26. (Pubitemid 26382454)
25. Gibaldi M, Perrier D., Pharmacokinetics. New York: Marcel Dekker, 1982.
26. DeRyke CA, Kuti JL, Nicolau DP., Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacotherapy. 2007; 27: 333-342. (Pubitemid 46327901)
27. Falagas ME, Karageorgopoulos DE., Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010; 375: 248-251.
28. Hanley MJ, Abernethy DR, Greenblatt DJ., Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010; 49: 71-87.
29. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS., Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother. 2006; 50: 1222-1227.
30. Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013; 57: 708-715.
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012.